Table 2.

Effect of canagliflozin versus glimepiride on albuminuria and eGFR with and without adjustments for covariates

CovariatesCanagliflozin 100 mg Versus GlimepirideCanagliflozin 300 mg Versus Glimepiride
Overall PopulationUACR≥30 mg/g SubgroupOverall PopulationUACR≥30 mg/g Subgroup
eGFR, ml/min per 1.73 m2 per yeara
 None2.8 (2.1 to 3.5)5.0 (2.9 to 7.0)2.4 (1.7 to 3.1)3.3 (1.2 to 5.4)
ΔHbA1c2.8 (2.1 to 3.5)5.0 (2.9 to 7.1)2.4 (1.7 to 3.1)3.3 (1.3 to 5.4)
ΔSBP2.8 (2.1 to 3.5)5.0 (2.9 to 7.0)2.4 (1.7 to 3.1)3.3 (1.2 to 5.4)
ΔBW2.8 (2.1 to 3.5)5.0 (2.9 to 7.0)2.4 (1.7 to 3.1)3.3 (1.2 to 5.4)
ΔHbA1c; ΔSBP; ΔBW2.8 (2.1 to 3.5)5.0 (2.9 to 7.1)2.4 (1.6 to 3.1)3.4 (1.3 to 5.5)
eGFR, ml/min per 1.73 m2b
 None2.7 (1.5 to 3.9)4.2 (1.6 to 7.4)1.5 (0.3 to 2.7)1.6 (–1.6 to 4.8)
ΔHbA1c3.3 (2.1 to 4.5)4.8 (1.5 to 8.1)2.1 (0.9 to 3.4)2.2 (–1.1 to 5.5)
ΔSBP3.0 (1.9 to 4.2)4.5 (1.3 to 7.7)1.9 (0.7 to 3.1)2.0 (–1.2 to 5.2)
ΔBW2.8 (1.6 to 4.0)3.9 (0.7 to 7.2)1.6 (0.3 to 2.8)1.4 (–1.9 to 4.6)
ΔHbA1c; ΔSBP; ΔBW3.7 (2.4 to 5.0)4.8 (1.5 to 8.2)2.6 (1.3 to 3.9)2.2 (–1.2 to 5.6)
Albuminuria, mg/g
 None−5.7 (−13.1 to 2.3)−31.7 (−48.9 to −8.6)−11.2 (−18.3 to −3.6)−49.3 (−62.2 to −31.9)
ΔHbA1c−6.2 (−13.5 to 1.7)−32.3 (−49.2 to −9.7)−10.9 (−17.8 to −3.3)−48.6 (−61.6 to −31.2)
ΔSBP−3.5 (−11.1 to 4.8)−28.9 (−46.7 to −5.3)−8.3 (−15.6 to −0.4)−47.1 (−60.4 to −29.4)
ΔBW−5.3 (−13.3 to 3.3)−30.3 (−48.6 to −5.5)−10.9 (−18.6 to −2.6)−48.8 (−62.5 to −30.0)
ΔHbA1c; ΔSBP; ΔBW−5.7 (−13.6 to 2.8)−28.7 (−47.0 to −4.1)−9.9 (−17.6 to −1.5)−46.3 (−60.4 to −27.2)
  • The least squares mean percent changes (95% CI) from baseline in albuminuria and the least squares mean change (95% CI) from baseline in eGFR over 2 years of follow-up are shown. ΔHbA1c, change in HbA1c; ΔSBP, change in systolic BP; ΔBW, change in body weight.

  • a Expressed as the difference in annual eGFR slope between canagliflozin and glimepiride.

  • b Expressed as the difference in least squares mean eGFR over 2 years of follow-up between canagliflozin and glimepiride.